Develops and sells prescription drugs focused on cancer, immunology, neuroscience, and heart disease—think Pfizer or Merck but Swiss-based.
USD 54.81B revenue (2025) with 75% gross margins and 26% net margins. Recurring from branded drugs with patent protection; high-margin prescription model.
Patent portfolios on blockbuster drugs create pricing power and customer lock-in, but patents expire and biosimilar competitors (Amgen, Eli Lilly) erode exclusivity over time.
Hold (sector percentile 40) — value B, growth C, profitability A-, momentum C-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Q2 revenue and EPS beat estimates, core operating profit grew, FY26 guidance reaffirmed.
Q2 net sales grew 1% in constant currencies to $14.4 billion; core operating income flat at $5.9 billion with 41.2% margin
Reuters reports investors focus on three major drug trial readouts in H2 to justify premium valuation
Boston Common sold 5,150 shares; Dimensional cut 4.9% but retains $1.24B stake
None yet
None yet
The user speculates Novartis' board may approve a major deal, evidenced by recent options activity. The discussion is a fundamental thesis based on potential deal news.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
